Clinical Competition Candidate
FINACEA
Dermatology · Rosacea
FINACEA carries product and use-code patents, moderate complexity (2/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 32 months away. Active clinical competition may compress the generic entry window.
LOE window
32months
to latest listed patent expiry (February 28, 2029)
Expiry attractiveness: 5/5
Patent profile
Substance patent (none)
Product / formulation patent (listed)
Use-code patent (listed)
Patent count: 4
Complexity score: 2/5
Clinical competition
Score: 5/5
Active trials linked: 52
Phase 2/3 trials: 19
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: AZELAIC ACID
Applicant (NDA holder): LEO PHARMA AS
Confidence: High
Market context
Therapeutic area: Dermatology
Indication: Rosacea
U.S. market size (est.)< $100M
Estimated U.S. net sales tier. Verify current figures before commercial diligence.